Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|October 1, 2026
7 Cardiology Headlines You Missed in September 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Advertisement
Advertisement
After a packed August, September 2026 was a comparatively quiet month for cardiology. However, despite having less in the way of major conferences and trial readouts, this past month made up for it with several major decisions from the
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Advertisement
Advertisement